[go: up one dir, main page]

MX2016009842A - Composicion farmaceutica que incluye 5-{4-(aminosulfonil) fenil}-2,2-dimetil-4-(3-fluorofenil)-3 (2h)-furanona y formulacion de capsula que incluye la composicion farmaceutica. - Google Patents

Composicion farmaceutica que incluye 5-{4-(aminosulfonil) fenil}-2,2-dimetil-4-(3-fluorofenil)-3 (2h)-furanona y formulacion de capsula que incluye la composicion farmaceutica.

Info

Publication number
MX2016009842A
MX2016009842A MX2016009842A MX2016009842A MX2016009842A MX 2016009842 A MX2016009842 A MX 2016009842A MX 2016009842 A MX2016009842 A MX 2016009842A MX 2016009842 A MX2016009842 A MX 2016009842A MX 2016009842 A MX2016009842 A MX 2016009842A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
furanone
aminosulfonyl
fluorophenyl
Prior art date
Application number
MX2016009842A
Other languages
English (en)
Other versions
MX367635B (es
Inventor
Ro Seonggu
Myung Cho Joong
Ha KIM Byung-
Yeon PARK Jae-
Ryong KIM Tae
Ii Ahn Sik
Original Assignee
Crystalgenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics Inc filed Critical Crystalgenomics Inc
Publication of MX2016009842A publication Critical patent/MX2016009842A/es
Publication of MX367635B publication Critical patent/MX367635B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que incluye (i) el compuesto de la fórmula 1 que se describe en la especificación o una sal farmacéuticamente aceptable del mismo, (ii) un diluyente farmacéuticamente aceptable y (iii) un lubricante farmacéuticamente aceptable. El compuesto de la fórmula 1 o la sal farmacéuticamente aceptable del mismo tiene un diámetro de partícula del volumen de 50% (d(0.5)) de 3 µm a 9 µm. La composición farmacéutica de la presente invención tiene las ventajas de una buena estabilidad, alta velocidad de disolución, uniformidad del contenido mejorada y propiedades farmacocinéticas excelentes. Debido a estas ventajas, la composición farmacéutica de la presente invención es eficaz para el tratamiento de inflamación o dolor.
MX2016009842A 2014-01-29 2015-01-29 Composición farmacéutica que incluye 5-{4-(aminosulfonil) fenil}-2,2-dimetil-4-(3-fluorofenil)-3(2h)-furanona y formulación de cápsula que incluye la composición farmacéutica. MX367635B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140011315A KR101446601B1 (ko) 2014-01-29 2014-01-29 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
PCT/KR2015/001002 WO2015115853A1 (en) 2014-01-29 2015-01-29 Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2016009842A true MX2016009842A (es) 2016-10-26
MX367635B MX367635B (es) 2019-08-28

Family

ID=51996334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009842A MX367635B (es) 2014-01-29 2015-01-29 Composición farmacéutica que incluye 5-{4-(aminosulfonil) fenil}-2,2-dimetil-4-(3-fluorofenil)-3(2h)-furanona y formulación de cápsula que incluye la composición farmacéutica.

Country Status (16)

Country Link
US (1) US20170000759A1 (es)
EP (1) EP3099294B1 (es)
JP (1) JP6250911B2 (es)
KR (1) KR101446601B1 (es)
CN (2) CN106029063A (es)
AU (1) AU2015211518B2 (es)
BR (1) BR112016017490B1 (es)
CA (1) CA2938036C (es)
ES (1) ES2694050T3 (es)
MX (1) MX367635B (es)
MY (1) MY181059A (es)
PH (1) PH12016501445B1 (es)
RU (1) RU2681932C2 (es)
SA (1) SA516371575B1 (es)
SG (1) SG11201605866YA (es)
WO (1) WO2015115853A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017971A (zh) * 2017-09-15 2023-11-10 晶体基因技术株式会社 用于治疗急性或慢性疼痛的药物组合物
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
HK1046413B (zh) * 1999-04-14 2005-05-27 株式会社太平洋 作为环加氧酶-2-抑制剂的4，5二芳基-3(2h)-呋喃酮衍生物
KR100495389B1 (ko) * 1999-04-14 2005-06-16 주식회사 태평양 시클로옥시게네이즈-2 저해제로서의4,5-디아릴-3(2ｈ)-퓨라논 유도체
EP1175214B1 (en) * 1999-12-08 2004-11-24 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US7220434B2 (en) * 1999-12-22 2007-05-22 Pharmacia Corporation (Of Pfizer, Inc.) Dual-release compositions of a cyclooxygenase-2 inhibitor
WO2005094815A1 (en) * 2004-03-30 2005-10-13 Amorepacific Corporation Dual inhibition of cyclooxygenase-2 and carbonic anhydrase
US20080306146A1 (en) * 2005-11-02 2008-12-11 Amorepacific Corporation Dosing Regimens for Cox-2 Inhibitor
KR20100096512A (ko) * 2009-02-24 2010-09-02 크리스탈지노믹스(주) 4,5-디아릴-3(2ｈ)-퓨라논 유도체 또는 그의 약학적으로 허용가능한 염을 포함하는 인지능력 개선용 약학 조성물
KR20130078147A (ko) * 2011-12-30 2013-07-10 한미약품 주식회사 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물

Also Published As

Publication number Publication date
ES2694050T3 (es) 2018-12-17
EP3099294A1 (en) 2016-12-07
JP6250911B2 (ja) 2017-12-20
AU2015211518A1 (en) 2016-07-21
MX367635B (es) 2019-08-28
KR101446601B1 (ko) 2014-10-07
CA2938036A1 (en) 2015-08-06
AU2015211518B2 (en) 2019-09-26
WO2015115853A1 (en) 2015-08-06
JP2017504639A (ja) 2017-02-09
US20170000759A1 (en) 2017-01-05
MY181059A (en) 2020-12-16
BR112016017490B1 (pt) 2023-04-18
RU2016127884A3 (es) 2018-09-17
SG11201605866YA (en) 2016-08-30
RU2016127884A (ru) 2018-03-01
EP3099294B1 (en) 2018-08-01
PH12016501445B1 (en) 2020-10-23
CN111419818A (zh) 2020-07-17
SA516371575B1 (ar) 2019-01-31
RU2681932C2 (ru) 2019-03-14
CN106029063A (zh) 2016-10-12
PH12016501445A1 (en) 2016-08-22
CA2938036C (en) 2021-07-13
BR112016017490A2 (pt) 2017-08-08
EP3099294A4 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA034243B9 (ru) Фармацевтические композиции, содержащие azd9291, для лечения рака
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
IN2013MU03577A (es)
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2018002006A (es) Benzamidas apareadas novedosas.
NZ700752A (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
EA201591649A1 (ru) Составы с органическими соединениями
JO3610B1 (ar) مشتقات كربوكساميد
MX380037B (es) Antagonistas novedosos 5-ht2
PH12016501445B1 (en) Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
WO2019104062A8 (en) Polymorphs and uses thereof
ZA202300107B (en) Pharmaceutically acceptable salts of sepiapterin
HK1228278A1 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration